179 related articles for article (PubMed ID: 23154267)
1. Starving tumors: inhibition of glycolysis reduces viability of human endometrial and ovarian cancer cells and enhances antitumor efficacy of GnRH receptor-targeted therapies.
Reutter M; Emons G; Gründker C
Int J Gynecol Cancer; 2013 Jan; 23(1):34-40. PubMed ID: 23154267
[TBL] [Abstract][Full Text] [Related]
2. Co-treatment of breast cancer cells with pharmacologic doses of 2-deoxy-D-glucose and metformin: Starving tumors.
Wokoun U; Hellriegel M; Emons G; Gründker C
Oncol Rep; 2017 Apr; 37(4):2418-2424. PubMed ID: 28350075
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of aerobic glycolysis enhances the anti-tumor efficacy of Zoptarelin Doxorubicin in triple-negative breast cancer cells.
Gründker C; Wokoun U; Hellriegel M; Emons G
J Obstet Gynaecol Res; 2019 Jul; 45(7):1334-1342. PubMed ID: 31016845
[TBL] [Abstract][Full Text] [Related]
4. Peptidomimetic GnRH antagonist AEZS-115 inhibits the growth of ovarian and endometrial cancer cells.
Engel JB; Hahne JC; Häusler SF; Meyer S; Segerer SE; Diessner J; Dietl J; Honig A
Anticancer Res; 2012 May; 32(5):2063-8. PubMed ID: 22593489
[TBL] [Abstract][Full Text] [Related]
5. Increase of doxorubicin-induced apoptosis after knock-down of gonadotropin-releasing hormone receptor expression in human endometrial, ovarian and breast cancer cells.
Fister S; Schlotawa L; Günthert AR; Emons G; Gründker C
Gynecol Endocrinol; 2008 Jan; 24(1):24-9. PubMed ID: 17943530
[TBL] [Abstract][Full Text] [Related]
6. Gonadotropin-releasing hormone type II antagonists induce apoptotic cell death in human endometrial and ovarian cancer cells in vitro and in vivo.
Fister S; Günthert AR; Emons G; Gründker C
Cancer Res; 2007 Feb; 67(4):1750-6. PubMed ID: 17308117
[TBL] [Abstract][Full Text] [Related]
7. AEZS-108 : a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors.
Engel J; Emons G; Pinski J; Schally AV
Expert Opin Investig Drugs; 2012 Jun; 21(6):891-9. PubMed ID: 22577891
[TBL] [Abstract][Full Text] [Related]
8. Targeted chemotherapy for triple-negative breast cancers via LHRH receptor.
Föst C; Duwe F; Hellriegel M; Schweyer S; Emons G; Gründker C
Oncol Rep; 2011 May; 25(5):1481-7. PubMed ID: 21331448
[TBL] [Abstract][Full Text] [Related]
9. GnRH-II agonist [D-Lys6]GnRH-II inhibits the EGF-induced mitogenic signal transduction in human endometrial and ovarian cancer cells.
Eicke N; Günthert AR; Emons G; Gründker C
Int J Oncol; 2006 Nov; 29(5):1223-9. PubMed ID: 17016655
[TBL] [Abstract][Full Text] [Related]
10. GnRH-II antagonists induce apoptosis in human endometrial, ovarian, and breast cancer cells via activation of stress-induced MAPKs p38 and JNK and proapoptotic protein Bax.
Fister S; Günthert AR; Aicher B; Paulini KW; Emons G; Gründker C
Cancer Res; 2009 Aug; 69(16):6473-81. PubMed ID: 19638591
[TBL] [Abstract][Full Text] [Related]
11. Antitumor effects of cecropin B-LHRH' on drug-resistant ovarian and endometrial cancer cells.
Li X; Shen B; Chen Q; Zhang X; Ye Y; Wang F; Zhang X
BMC Cancer; 2016 Mar; 16():251. PubMed ID: 27021903
[TBL] [Abstract][Full Text] [Related]
12. Effective targeted chemotherapy using AEZS-108 (AN-152) for LHRH receptor-positive pancreatic cancers.
Gründker C; Ernst J; Reutter MD; Ghadimi BM; Emons G
Oncol Rep; 2011 Sep; 26(3):629-35. PubMed ID: 21667032
[TBL] [Abstract][Full Text] [Related]
13. Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells.
Treeck O; Wackwitz B; Haus U; Ortmann O
Gynecol Oncol; 2006 Aug; 102(2):292-9. PubMed ID: 16443261
[TBL] [Abstract][Full Text] [Related]
14. Antiproliferative effects of the GnRH antagonist cetrorelix and of GnRH-II on human endometrial and ovarian cancer cells are not mediated through the GnRH type I receptor.
Gründker C; Schlotawa L; Viereck V; Eicke N; Horst A; Kairies B; Emons G
Eur J Endocrinol; 2004 Jul; 151(1):141-9. PubMed ID: 15248835
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of glycolysis enhances cisplatin-induced apoptosis in ovarian cancer cells.
Loar P; Wahl H; Kshirsagar M; Gossner G; Griffith K; Liu JR
Am J Obstet Gynecol; 2010 Apr; 202(4):371.e1-8. PubMed ID: 20138251
[TBL] [Abstract][Full Text] [Related]
16. Dual blockade of PI3K/AKT/mTOR (NVP-BEZ235) and Ras/Raf/MEK (AZD6244) pathways synergistically inhibit growth of primary endometrioid endometrial carcinoma cultures, whereas NVP-BEZ235 reduces tumor growth in the corresponding xenograft models.
Schrauwen S; Depreeuw J; Coenegrachts L; Hermans E; Lambrechts D; Amant F
Gynecol Oncol; 2015 Jul; 138(1):165-73. PubMed ID: 25933683
[TBL] [Abstract][Full Text] [Related]
17. Targeted chemotherapy of endometrial, ovarian and breast cancers with cytotoxic analogs of luteinizing hormone-releasing hormone (LHRH).
Engel JB; Schally AV; Buchholz S; Seitz S; Emons G; Ortmann O
Arch Gynecol Obstet; 2012 Aug; 286(2):437-42. PubMed ID: 22555802
[TBL] [Abstract][Full Text] [Related]
18. Old and new perspectives in the pharmacological treatment of advanced or recurrent endometrial cancer: Hormonal therapy, chemotherapy and molecularly targeted therapies.
Gadducci A; Cosio S; Genazzani AR
Crit Rev Oncol Hematol; 2006 Jun; 58(3):242-56. PubMed ID: 16436330
[TBL] [Abstract][Full Text] [Related]
19. PK11195 enhances chemosensitivity to cisplatin and paclitaxel in human endometrial and ovarian cancer cells.
Takai N; Ueda T; Nishida M; Nasu K; Narahara H
Int J Mol Med; 2010 Jan; 25(1):97-103. PubMed ID: 19956907
[TBL] [Abstract][Full Text] [Related]
20. Gonadotropin-releasing hormone type II induces apoptosis of human endometrial cancer cells by activating GADD45alpha.
Wu HM; Cheng JC; Wang HS; Huang HY; MacCalman CD; Leung PC
Cancer Res; 2009 May; 69(10):4202-8. PubMed ID: 19366794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
